NCI Considering Adoption Of NIGMS Guidelines To Limit Growth Of Renewals, Ensure New Grants
In Brief: Three Patients Evaluated For Gene Therapy; Revised Program Instructions Available
Joseph Cullen, Cancer Prevention Leader, Dead At 54
‘Major Discover’ At FCRDC Is NF1 Gene, Report Says
DCT Advisors Reject MRS Concept, Approve RDOG Expansion
DCT Board Approves Drug Development Recompetition
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”